{"schema_version":"1","generated_at":"2026-11-04T07:23:44.096Z","data_as_of":null,"url":"https://www.findmykol.com/kol/marshall-mckenna","json_url":"https://www.findmykol.com/kol/marshall-mckenna/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"marshall-mckenna","name":"Marshall McKenna","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"Rutgers Cancer Institute","institution_url":"https://www.findmykol.com/institution/rutgers-cancer-institute","city":"Newark","state":"NJ","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1063940963","openalex":"A5041766938"},"summary":"Marshall McKenna is a Hematology physician affiliated with Rutgers Cancer Institute. OpenAlex indexes 31 publications with 312 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":31,"cited_by_count":312,"h_index":8,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"Regeneron","program_year":2024,"amount_usd":1264.11,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063940963"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2024,"amount_usd":400,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063940963"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1063940963","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Blood & clotting","share_pct":100,"classes_total":1,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Eliquis","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":31,"shown":5,"withheld":26,"matched_by":"OpenAlex author record","recent":[{"title":"A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group","year":2026,"journal":"Cancers","source_url":"https://doi.org/10.3390/cancers18050740","status":"verified"},{"title":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025029117","status":"verified"},{"title":"Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-402","status":"verified"},{"title":"Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-401","status":"verified"},{"title":"Use of BCMA Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Versus BCMA T-Cell Engagers in BCMA-Exposed Relapsed/Refractory Multiple Myeloma","year":2025,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.01.641","status":"verified"}],"source":"works"},"contact":{"address_1":"150 BERGEN ST # UH-I248","city":"Newark","state":"NJ","zip":"071032496","phone":"973-972-6056","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1063940963","source":"identity"},"similar":[{"name":"Christian Hinrichs","slug":"christian-hinrichs","institution":"Rutgers Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/christian-hinrichs","json_url":"https://www.findmykol.com/kol/christian-hinrichs/profile.json"},{"name":"Tina Mayer","slug":"tina-mayer","institution":"Rutgers Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/tina-mayer","json_url":"https://www.findmykol.com/kol/tina-mayer/profile.json"},{"name":"Bo Qin","slug":"bo-qin-us","institution":"Rutgers Cancer Institute","url":"https://www.findmykol.com/kol/bo-qin-us","json_url":"https://www.findmykol.com/kol/bo-qin-us/profile.json"},{"name":"Lara Hathout","slug":"lara-hathout","institution":"Rutgers Cancer Institute","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/lara-hathout","json_url":"https://www.findmykol.com/kol/lara-hathout/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"},{"name":"Jaroslaw Maciejewski","slug":"jaroslaw-maciejewski","institution":"Cleveland Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/jaroslaw-maciejewski","json_url":"https://www.findmykol.com/kol/jaroslaw-maciejewski/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":26}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-04-03","provider_certified":"2025-04-03","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}